Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time

被引：0
|
作者：
Jiang, Di Maria [1 ]
Hamilton, Robert J. [2 ]
Hansen, Aaron R. [1 ]
机构：
[1] Univ Toronto, Div Med Oncol & Haematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Div Urol, Dept Surg Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2020年 / 14卷 / 02期
关键词：
PHASE-III; CISPLATIN; IFOSFAMIDE; PACLITAXEL; ETOPOSIDE;
D O I：
10.5489/cuaj.6407
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [21] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
  • [22] Intraperitoneal chemotherapy as first-line treatment in the management of epithelial ovarian cancer
    Rekhraj, S.
    Kinross, J.
    Prabhudesai, S.
    Darzi, A.
    Ziprin, P.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (05) : 509 - 517
  • [23] Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma
    Usakova, V.
    Sevcikova, K.
    Usak, J.
    Bartosova, Z.
    Mikulova, M.
    Spanik, S.
    NEOPLASMA, 2013, 60 (01) : 83 - 91
  • [24] First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
    Hwang, Jun-Eul
    Kim, Ha-Na
    Kim, Dae-Eun
    Shim, Hyun-Jeong
    Bae, Woo-Kyun
    Hwang, Eu-Chang
    Cho, Sang-Hee
    Chung, Ik-Joo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (04) : 562 - 568
  • [25] Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
    Fizazi, Karim
    Le Teuff, Gwenael
    Flechon, Aude
    Pagliaro, Lance
    Mardiak, Josef
    Geoffrois, Lionnel
    Laguerre, Brigitte
    Chevreau, Christine
    Delva, Remy
    Rolland, Frederic
    Theodore, Christine
    Roubaud, Guilhem
    Gravis, Gwenaelle
    Eymard, Jean-Christophe
    Cancel, Mathilde
    Juzyna, Beata
    Reckova, Maria
    Naoun, Natacha
    Logothetis, Christopher
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (28) : 3270 - 3276
  • [26] Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours
    Beausoleil, Michel
    Ernst, D. Scott
    Stitt, Larry
    Winquist, Eric
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2012, 6 (02): : 111 - 116
  • [27] Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients
    Gossi, Flavio
    Spahn, Martin
    Samaras, Panagiotis
    Beyer, Jorg
    Schardt, Julian
    Pabst, Thomas
    BONE MARROW TRANSPLANTATION, 2018, 53 (07) : 820 - 825
  • [28] First-line treatment in metastatic colorectal cancer: Important or crucial?
    Malka, David
    Rotolo, Federico
    Boige, Valerie
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 363 - 366
  • [29] Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer
    Prithviraj, G. K.
    Baksh, K.
    Fulp, W.
    Meredith, K.
    Hoffe, S.
    Shridhar, R.
    Almhanna, K.
    DISEASES OF THE ESOPHAGUS, 2015, 28 (08) : 782 - 787
  • [30] Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India
    Joshi, A.
    Zanwar, S.
    Shetty, N.
    Patil, V
    Noronha, V
    Bakshi, G.
    Prakash, G.
    Menon, S.
    Prabhash, K.
    INDIAN JOURNAL OF CANCER, 2016, 53 (02) : 313 - 316
12345